Among patients with noncirrhotic chronic hepatitis B, concurrent MASLD may not affect fibrosis progression. Concurrent metabolic dysfunction-associated steatotic liver disease (MASLD) is not ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — The risk for advanced fibrosis was similar among patients with lean and non-lean metabolic ...

Please provide your email address to receive an email when new articles are posted on . Food insecurity was linked with lower odds of MASLD in patients with HIV, but greater odds for fibrosis among ...

Liver stiffness and severe fibrosis, as measured by FibroScan, are independently linked to type 2 diabetes (T2DM) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), new ...

(A) Representative histological images of liver tissues from patients with steatosis, MASH, and liver fibrosis by hematoxylin-eosin or Masson's trichrome staining. The arrows mark the ballooned ...

Data regarding risk factors and long-term outcomes of U.S. patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. This study aimed to investigate the ...

Researchers compared the clinical and economic differences between two agents approved to treat metabolic ...

New research and updated guidelines highlight the urgent need to standardize noninvasive liver fibrosis screening as metabolic dysfunction-associated steatotic liver disease (MASLD) cases climb ...

News and commentary from the world of gastroenterology and hepatology ...